{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T23:08:22Z","timestamp":1788736102852,"version":"build-2803163510"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctrv.2026.103180","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T01:07:39Z","timestamp":1783991259000},"page":"103180","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Management of cancer-associated thrombosis in patients with gastrointestinal cancers: lights and shadows"],"prefix":"10.1016","volume":"149","author":[{"given":"Lorenzo","family":"Gervaso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Cioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelia Marina","family":"Rosanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Alessandra","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctrv.2026.103180_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat Rev Dis Primers"},{"issue":"23","key":"10.1016\/j.ctrv.2026.103180_bb0010","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer\u2014a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103180_bb0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-062768","article-title":"Risk and timing of venous thromboembolism in patients with gastrointestinal cancer: a nationwide Danish cohort study","volume":"13","author":"T\u00f8nnesen","year":"2023","journal-title":"BMJ Open"},{"key":"10.1016\/j.ctrv.2026.103180_bb0020","doi-asserted-by":"crossref","unstructured":"Couturaud F, Mah\u00e9 I, Schmidt J, et al. Adult breast, lung, pancreatic, upper and lower gastrointestinal cancer patients with hospitalized venous thromboembolism in the national French hospital discharge database. BMC Cancer 2023;23(1):531. Published 2023 Jun 10. doi:https:\/\/doi.org\/10.1186\/s12885-023-10877-4.","DOI":"10.1186\/s12885-023-10877-4"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103180_bb0025","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1002\/ajh.27106","article-title":"Long-term risk of venous thromboembolism among patients with gastrointestinal non-neoplastic and neoplastic diseases: a prospective cohort study of 484 211 individuals","volume":"99","author":"Yuan","year":"2024","journal-title":"American J Hematol"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103180_bb0030","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with Cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103180_bb0035","doi-asserted-by":"crossref","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch Intern Med"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103180_bb0040","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.1111\/jth.15487","article-title":"Venous thromboembolism associated with central venous catheters in patients with cancer: from pathophysiology to thromboprophylaxis, areas for future studies","volume":"19","author":"Debourdeau","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103180_bb0045","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1111\/imj.14780","article-title":"Catheter-related thrombosis incidence and risk factors in adult cancer patients with central venous access devices","volume":"50","author":"Ellis","year":"2020","journal-title":"Intern Med J"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103180_bb0050","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.3324\/haematol.2023.284778","article-title":"Targeted anti-cancer agents and risk of venous thromboembolism","volume":"109","author":"Verso","year":"2024","journal-title":"Haematologica"},{"issue":"29","key":"10.1016\/j.ctrv.2026.103180_bb0055","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1200\/JCO.2009.22.3271","article-title":"Assessing risk of venous thromboembolism in the patient with Cancer","volume":"27","author":"Khorana","year":"2009","journal-title":"JCO"},{"issue":"25","key":"10.1016\/j.ctrv.2026.103180_bb0060","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"JCO"},{"issue":"19","key":"10.1016\/j.ctrv.2026.103180_bb0065","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in Cancer patients: a Meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.ctrv.2026.103180_bb0070","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ejca.2021.09.010","article-title":"Immune checkpoint inhibitors for cancer and venous thromboembolic events","volume":"158","author":"Gong","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103180_bb0075","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010761","article-title":"Immune checkpoint inhibitor-associated risk for venous thromboembolism: a comprehensive analysis","volume":"13","author":"Sussman","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103180_bb0080","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/COC.0000000000000981","article-title":"Characteristics and outcomes of cancer patients with venous thromboembolic events after treatment with immune checkpoint inhibitors","volume":"46","author":"Dutra","year":"2023","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103180_bb0085","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1055\/s-0043-1769609","article-title":"Risk factors of venous thromboembolic disease in cancer patients treated with immune checkpoint inhibitor","volume":"123","author":"Le S\u00e8ve","year":"2023","journal-title":"Thromb Haemost"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103180_bb0090","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/ijc.30280","article-title":"Systematic review and meta-analysis of the risk of severe and life-threatening thromboembolism in cancer patients receiving anti-EGFR monoclonal antibodies (cetuximab or panitumumab)","volume":"139","author":"Miroddi","year":"2016","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103180_bb0095","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103180_bb0100","first-page":"173","article-title":"Venous and arterial thromboembolism in patients with Cancer","volume":"3","author":"Gervaso","year":"2021","journal-title":"JACC: CardioOncology"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103180_bb0105","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/MOH.0000000000000862","article-title":"Scoring systems to predict thrombotic complications in solid tumor patients","volume":"32","author":"Sharma","year":"2025","journal-title":"Curr Opin Hematol"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103180_bb0110","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"The Lancet Haematology"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103180_bb0115","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian Cancer: the prospective COMPASS\u2013Cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103180_bb0120","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory Cancer patients: the ONKOTEV study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2026.103180_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114234","article-title":"Comparison of Khorana vs. ONKOTEV predictive score to individualize anticoagulant prophylaxis in outpatients with cancer","volume":"209","author":"Cella","year":"2024","journal-title":"Eur J Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2026.103180_bb0130","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.22.01542","article-title":"Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103180_bb0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.54352","article-title":"Risk of venous thromboembolic events after surgery for Cancer","volume":"7","author":"Bj\u00f6rklund","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103180_bb0140","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103180_bb0145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103180_bb0150","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103180_bb0155","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.amjsurg.2018.11.046","article-title":"Extended thromboprophylaxis with low-molecular weight heparin (LMWH) following abdominopelvic cancer surgery","volume":"218","author":"Carrier","year":"2019","journal-title":"Am J Surg"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103180_bb0160","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1097\/SLA.0000000000000340","article-title":"A randomized study on 1-week versus 4-week prophylaxis for venous thromboembolism after laparoscopic surgery for colorectal cancer","volume":"259","author":"Vedovati","year":"2014","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103180_bb0165","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.2022015796","article-title":"Rivaroxaban vs placebo for extended antithrombotic prophylaxis after laparoscopic surgery for colorectal cancer","volume":"140","author":"Becattini","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2026.103180_bb0170","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with Cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"JCO"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103180_bb0175","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1111\/j.1538-7836.2010.04044.x","article-title":"A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score","volume":"8","author":"Barbar","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103180_bb0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102441","article-title":"Validation of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) risk scores for venous thromboembolism and bleeding in an independent population","volume":"8","author":"Wilkinson","year":"2024","journal-title":"Res Pract Thromb Haemost."},{"issue":"20","key":"10.1016\/j.ctrv.2026.103180_bb0185","first-page":"1945","article-title":"MAGELLAN Steering Committee. Rivaroxaban for thromboprophylaxis in acutely ill medical patients","volume":"368","author":"Cohen","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103180_bb0190","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1634\/theoncologist.2013-0226","article-title":"Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis","volume":"18","author":"Lyman","year":"2013","journal-title":"Oncologist"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103180_bb0195","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103180_bb0200","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2026.103180_bb0205","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1200\/jco.2012.30.15_suppl.4044","article-title":"Evaluation of predictive factors for thromboembolic events in patients with advanced pancreatic cancer: evaluation of the CONKO-004 (PROSPECT) study cohort","volume":"30","author":"Pelzer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103180_bb0210","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2026.103180_bb0215","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12549","article-title":"Rivaroxaban thromboprophylaxis for gastric\/gastroesophageal junction tumors versus other tumors: a post hoc analysis of the randomized CASSINI trial","volume":"5","author":"Mones","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"issue":"8","key":"10.1016\/j.ctrv.2026.103180_bb0220","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1016\/j.jtha.2023.04.010","article-title":"Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study","volume":"21","author":"Lap\u00e9bie","year":"2023","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ctrv.2026.103180_bb0225","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer","volume":"349","author":"Lee","year":"2003","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ctrv.2026.103180_bb0230","article-title":"Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer","volume":"6","author":"Akl","year":"2011","journal-title":"Cochrane Database Syst Rev."},{"issue":"6","key":"10.1016\/j.ctrv.2026.103180_bb0235","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1111\/jth.12923","article-title":"Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN study","volume":"13","author":"Francis","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.ctrv.2026.103180_bb0240","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.thromres.2017.07.004","article-title":"Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study","volume":"157","author":"Jara-Palomares","year":"2017","journal-title":"Thromb Res"},{"key":"10.1016\/j.ctrv.2026.103180_bb0245","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for Cancer-associated venous thromboembolism","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ctrv.2026.103180_bb0250","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ctrv.2026.103180_bb0255","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral factor xa inhibitor with low molecular weight heparin in patients with Cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2026.103180_bb0260","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2026.103180_bb0265","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol Oncol."},{"issue":"7","key":"10.1016\/j.ctrv.2026.103180_bb0270","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/jth.14149","article-title":"Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis","volume":"16","author":"Marin-Barrera","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.ctrv.2026.103180_bb0275","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1038\/s41591-025-03918-x","article-title":"Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial","volume":"31","author":"Marchetti","year":"2025","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103180_bb0280","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/jth.15215","article-title":"Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: a cohort study","volume":"19","author":"Roopkumar","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103180_bb0285","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1001\/jamaoncol.2023.3625","article-title":"Prevalence of thromboembolic events in patients with non-small cell lung Cancer and RET fusions","volume":"9","author":"Aldea","year":"2023","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2026.103180_bb0290","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1182\/blood-2004-05-2042","article-title":"Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumor progression and angiogenesis","volume":"105","author":"Yu","year":"2005","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctrv.2026.103180_bb0295","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1007\/s12094-020-02339-1","article-title":"Incidence of venous thromboembolism in patients with colorectal cancer according to oncogenic status","volume":"22","author":"Ortega Mor\u00e1n","year":"2020","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2026.103180_bb0300","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2025.43.4_suppl.634","article-title":"Genomic alterations as predictive biomarkers for cancer-associated thrombosis (CAT) in biliary tract cancer (BTC)","volume":"43","author":"Pirozzi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"4_suppl","key":"10.1016\/j.ctrv.2026.103180_bb0305","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1200\/JCO.2025.43.4_suppl.751","article-title":"Beyond Khorana score 2: molecular correlates of venous thromboembolism in pancreatic cancer","volume":"43","author":"Lemay","year":"2025","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.ctrv.2026.103180_bb0310","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II Colon Cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ctrv.2026.103180_bb0315","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-023-02791-w","article-title":"Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer","volume":"30","author":"Shitara","year":"2024","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ctrv.2026.103180_bb0320","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.trecan.2023.08.011","article-title":"Variant allele frequency: a decision-making tool in precision oncology?","volume":"9","author":"Boscolo Bielo","year":"2023","journal-title":"Trends Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2026.103180_bb0325","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1038\/s41591-024-03195-0","article-title":"DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism","volume":"30","author":"Jee","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2026.103180_bb0330","doi-asserted-by":"crossref","first-page":"4013","DOI":"10.1182\/blood-2023-184751","article-title":"Circulating tumor DNA and risk of venous thromboembolism in locally advanced rectal cancer","volume":"142","author":"Gervaso","year":"2023","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737226000940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:27:54Z","timestamp":1788733674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737226000940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":66,"alternative-id":["S0305737226000940"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103180","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of cancer-associated thrombosis in patients with gastrointestinal cancers: lights and shadows","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2026.103180","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103180"}}